Vilazodone Inclusion Complex Eliminates Food Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vilazodone, an antidepressant, has significant food effects, with bioavailability reduced by 50-60% when taken on an empty stomach, making it inconvenient for patients with depression who often experience loss of appetite, leading to poor compliance and treatment outcomes.
Innovation Solution
A composition comprising an inclusion complex where vilazodone or its pharmaceutically acceptable salt is wrapped in an inclusion material, such as cyclodextrin or its derivatives, to form a bioequivalent formulation with specifications of 8-9 mg, 16-18 mg, or 32-36 mg, which can be taken on an empty stomach or with food, eliminating food effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If vilazodone is taken on an empty stomach, then the convenience for patients with loss of appetite is improved, but the bioavailability is reduced by 50-60%
Solution Approach 1:
The patent uses cyclodextrin as an intermediary substance to form an inclusion complex with vilazodone. The cyclodextrin cavity encapsulates the vilazodone molecule, modifying its solubility and dissolution characteristics. This intermediary structure allows the drug to be taken on an empty stomach without the severe bioavailability reduction that would otherwise occur
Solution Approach 2:
The patent changes the physical and chemical parameters of vilazodone by forming an inclusion complex. The complexation alters the drug's solubility, dissolution rate, and stability parameters, enabling consistent bioavailability regardless of fasting or fed state. The specification adjustment (8-9 mg, 16-18 mg, or 32-36 mg) also represents a parameter change to optimize therapeutic effect while eliminating food effects
2Quantity of substance
If vilazodone is taken with food, then the bioavailability is improved to about 72%, but the convenience for patients with loss of appetite deteriorates
Solution Approach 1:
Cyclodextrin serves as a mediator that decouples the relationship between food intake and drug absorption. The inclusion complex protects vilazodone from food-induced precipitation and maintains consistent dissolution kinetics, making food intake unnecessary for achieving adequate bioavailability
Solution Approach 2:
Instead of requiring food to enhance absorption, the patent inverts the approach by using cyclodextrin complexation to achieve food-independent absorption. The inclusion complex fundamentally reverses the conventional requirement that vilazodone must be taken with food to ensure adequate bioavailability
3Reliability
If the dosage is increased to improve treatment effect, then the therapeutic efficacy is improved, but the adverse reactions increase
Solution Approach 1:
The patent optimizes the dosage parameters by adjusting the vilazodone specification (8-9 mg, 16-18 mg, or 32-36 mg) in the inclusion complex formulation. This parameter optimization achieves the desired therapeutic effect while minimizing adverse reactions, representing a more favorable risk-benefit profile compared to conventional dosing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vilazodone inclusion complex formulation achieves bioequivalence to commercial preparations, ensuring consistent pharmacokinetics whether taken with or without food, thereby improving patient compliance and treatment efficacy.
Implementation Method 1
an inclusion complex, the inclusion complex comprises an active ingredient wrapped in an inclusion material
Data Source
AI summary
A vilazodone composition, a pharmaceutical preparation thereof, a preparation therefor, and a use thereof, relating to the pharmaceutical field. The composition contains an inclusion compound, the inclusion compound containing an active ingredient wrapped in an inclusion material; and the specification of the pharmaceutical preparation is 8 mg to 9 mg, 16 mg to 18 mg, or 32 mg to 36 mg. Under the condition that the specification of the pharmaceutical preparation can be reduced, the pharmacokinetics effect of the pharmaceutical preparation in a human body can still be equivalent to that of a reference listed drug, and the pharmaceutical preparation has an unexpected technical effect.